{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Equillium, Inc."},"Symbol":{"label":"Symbol","value":"EQ"},"Address":{"label":"Address","value":"2223 AVENIDA DE LA PLAYA,SUITE 105, LA JOLLA, California, 92037, United States"},"Phone":{"label":"Phone","value":"+1 858 240-1200"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease."},"CompanyUrl":{"label":"Company Url","value":"https://www.equilliumbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bruce D. Steel","title":"President, Chief Executive Officer & Director"},{"name":"Christine Zedelmayer","title":"Chief Operating Officer & Senior Vice President"},{"name":"Stephen Connelly","title":"Director & Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}